Form 4: Beam Therapeutics SVP, Finance and Treasurer Reports Stock Transactions
SEC Form 4 Filing
Bethany J Cavanagh, SVP, Finance and Treasurer of Beam Therapeutics, reports acquisition of restricted stock units and sale of common stock to cover tax obligations.
Summary
- On September 30, 2024, Bethany J Cavanagh, SVP, Finance and Treasurer of Beam Therapeutics Inc., acquired 2,500 restricted stock units (RSUs) under the company's 2019 Equity Incentive Plan.
- Each RSU represents the right to receive one share of BEAM's common stock, vesting in four equal annual installments.
- On October 1, 2024, Cavanagh sold 289 shares of common stock at an average price of $23.4791 to cover tax withholding obligations upon the vesting of RSUs granted on September 30, 2021.
- The sale was executed under a Rule 10b5-1 trading plan adopted before February 27, 2023.
- Following these transactions, Cavanagh beneficially owns 44,931 shares of Beam Therapeutics Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation and tax obligations, with no indication of unusual activity or concerns.
Positives
- The acquisition of RSUs indicates continued alignment of the executive's interests with the company's long-term performance.
- The use of a pre-existing 10b5-1 trading plan suggests transparency and avoids concerns about insider trading.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Comparison to Industry Standards
- Similar transactions are common among executives in publicly traded companies, particularly in the biotechnology sector where equity compensation is a significant part of overall remuneration.
- The use of Rule 10b5-1 trading plans is a standard practice to ensure compliance with insider trading regulations, comparable to practices at companies like CRISPR Therapeutics and Editas Medicine.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they are routine and conducted under a pre-existing trading plan.
- Transparency is increased for shareholders through the disclosure of these transactions.
Key Dates
| Date | Description |
|---|---|
| February 27, 2023 | Date prior to which the Rule 10b5-1 trading plan was adopted. |
| September 30, 2021 | Date of grant of RSUs that triggered the tax obligation. |
| September 30, 2024 | Date of RSU acquisition. |
| October 01, 2024 | Date of common stock sale. |
| October 02, 2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.